

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following completion of the [REDACTED] and assuming the [REDACTED] is not exercised and no other changes are made to the issued share capital of our Company from the Latest Practicable Date to the [REDACTED], the following persons will have interests or short positions (if applicable) in the Shares or underlying Shares, which would be required to be disclosed to our Company and the Stock Exchange pursuant to the provisions in Divisions 2 and 3 of Part XV of the SFO, or be interested, directly or indirectly, in 10% or more of the nominal value of any class, or be interested, directly or indirectly, in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at Shareholders’ general meetings of our Company:

Name of Shareholders	Nature of interest	Description of Shares	Number of Shares	Approximate % of the total issued share capital of our Company as of the Latest Practicable Date	Immediately after the [REDACTED]	
					Approximate % of the A Shares of our Company	Approximate % of the total issued share capital of our Company
Future Industry Investment Fund (Limited Partnership) (先進製造產業投資基金(有限合伙)) (“FIIF”) ⁽¹⁾	Beneficial owner	A Shares	108,923,023	23.42%	[23.42]%	[REDACTED]%
AstraZeneca AB ⁽²⁾	Beneficial owner	A Shares	108,923,023	23.42%	[23.42]%	[REDACTED]%
Jiangsu Wuxi Dizhe Enterprise Management Partnership (Limited Partnership) (江蘇無錫迪喆企業管理合夥企業(有限合伙)) (“Wuxi Dizhe”) ⁽³⁾	Beneficial interest	A Shares	57,451,788	12.35%	[12.35]%	[REDACTED]%
	Interests held jointly with another person ⁽⁵⁾	A Shares	14,201,255	3.05%	[3.05]%	[REDACTED]%
Dr. Zhang Xiaolin (張小林)	Beneficial interest	A Shares	9,033,972	1.94%	[1.94]%	[REDACTED]%
	Interest in controlled corporation; Interests held jointly with another person ⁽³⁾⁽⁴⁾⁽⁵⁾	A Shares	62,619,071	13.46%	[13.46]%	[REDACTED]%
ZYTZ Partners Limited (“ZYTZ”) ⁽⁵⁾	Beneficial interest	A Shares	5,167,283	1.11%	[1.11]%	[REDACTED]%
	Interests held jointly with another person	A Shares	66,485,760	14.29%	[14.29]%	[REDACTED]%

Notes:

- (1) FIIF, a limited partnership established in the PRC, is managed by its general partner, SDICFUND Management Co., Ltd. (國投創新投資管理有限公司) (“SDICFUND”). SDICFUND is 40% owned by China SDIC Gaoxin Industrial Investment Co., Ltd. (中國國投高新產業投資有限公司), which in turn is controlled by State Development and Investment Group Co., Ltd. (國家開發投資集團有限公司), a state-owned enterprise. As such, under the SFO, each of State Development and Investment Group Co., Ltd., China State Investment High-Tech Industrial Investment Co., Ltd. and SDICFUND is deemed to be interested in Shares held by FIIF.
- (2) As of the Latest Practicable Date, AZAB is a wholly owned subsidiary of AstraZeneca PLC. As such, under the SFO, AstraZeneca PLC is deemed to be interested in Shares held by AZAB.
- (3) As of the Latest Practicable Date, Wuxi Sinokeen Business Consulting Co., Ltd. (無錫敦禾商務諮詢有限責任公司) (“Wuxi Sinokeen”) acts as the general partner of Wuxi Dizhe. The limited partnership interests in Wuxi Dizhe are held as to (a) 61.11% by Dr. Zhang Xiaolin; and (b) the remaining 38.89% by 35 other limited partners, each holding less than 30% interest therein. Wuxi Sinokeen is owned as to 90% and 10% by Dr. Zhang Xiaolin, being our founder, chairperson of the Board, executive Director and Chief Executive Officer and Dr. Yang Zhenfan (楊振帆), being our deputy general manager and chief medical officer, respectively. As such, under the SFO, Dr. Zhang Xiaolin is deemed to be interested in the Shares held by Wuxi Dizhe.
- (4) As of the Latest Practicable Date, ZYTZ is wholly-owned by Dezent Partners Limited, which is in turn 75% owned by Dr. Zhang Xiaolin. As such, under the SFO, Dr. Zhang Xiaolin is deemed to be interested in the Shares held by ZYTZ.
- (5) As advised by our PRC Legal Advisor, Dr. Zhang Xiaolin is deemed to be a person acting in concert with Wuxi Dizhe and ZYTZ. As such, under the SFO, each of Wuxi Dizhe, Dr. Zhang Xiaolin and ZYTZ are deemed to be interested in the Shares held by the others therein.

For further information on any other person who will be, immediately following completion of the [REDACTED], directly or indirectly, interested in 10% or more of the issued voting shares of our subsidiaries, see “Appendix VI — Statutory and General Information — Further Information about Our Directors and Substantial Shareholders — Interests of Substantial Shareholders — Interests in our Company’s subsidiaries.”